These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 17097943

  • 1. Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients.
    San Segundo D, Ruiz JC, Fernández-Fresnedo G, Izquierdo M, Gómez-Alamillo C, Cacho E, Benito MJ, Rodrigo E, Palomar R, López-Hoyos M, Arias M.
    Transplant Proc; 2006 Oct; 38(8):2391-3. PubMed ID: 17097943
    [Abstract] [Full Text] [Related]

  • 2. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, López-Hoyos M, Arias M.
    Transplantation; 2006 Aug 27; 82(4):550-7. PubMed ID: 16926600
    [Abstract] [Full Text] [Related]

  • 3. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors.
    San Segundo D, Fábrega E, López-Hoyos M, Pons F.
    Transplant Proc; 2007 Sep 27; 39(7):2290-2. PubMed ID: 17889166
    [Abstract] [Full Text] [Related]

  • 4. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
    Chu ZQ, Ji Q.
    Transplant Proc; 2013 Sep 27; 45(1):153-6. PubMed ID: 23375290
    [Abstract] [Full Text] [Related]

  • 5. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation.
    Korczak-Kowalska G, Wierzbicki P, Bocian K, Klosowska D, Niemczyk M, Wyzgal J, Korecka A, Durlik M, Chmura A, Paczek L, Górski A.
    Transplant Proc; 2007 Nov 27; 39(9):2721-3. PubMed ID: 18021968
    [Abstract] [Full Text] [Related]

  • 6. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 7. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR.
    J Heart Lung Transplant; 2006 May 27; 25(5):518-22. PubMed ID: 16678029
    [Abstract] [Full Text] [Related]

  • 8. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
    Li Y, Shi Y, Huang Z, Bai Y, Niu Q, Cai B, Wang L, Feng W.
    Int Immunopharmacol; 2011 Dec 27; 11(12):2033-8. PubMed ID: 21911083
    [Abstract] [Full Text] [Related]

  • 9. Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression.
    Kandaswamy R, Humar A, Casingal V, Gillingham KJ, Ibrahim H, Matas AJ.
    Transplantation; 2007 Mar 27; 83(6):722-6. PubMed ID: 17414704
    [Abstract] [Full Text] [Related]

  • 10. Regulatory T cells in renal transplantation and modulation by immunosuppression.
    López-Hoyos M, Segundo DS, Fernández-Fresnedo G, Marín MJ, González-Martín V, Arias M.
    Transplantation; 2009 Aug 15; 88(3 Suppl):S31-9. PubMed ID: 19667959
    [Abstract] [Full Text] [Related]

  • 11. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 15; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 12. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, Portales-Pérez D.
    Transpl Immunol; 2009 May 15; 21(1):43-9. PubMed ID: 19233271
    [Abstract] [Full Text] [Related]

  • 13. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 15; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 14. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A, Campistol JM, Lario S, Oppenheimer F, Diekmann F.
    Transplant Proc; 2007 Sep 15; 39(7):2138-41. PubMed ID: 17889117
    [Abstract] [Full Text] [Related]

  • 15. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation.
    van de Wetering J, Koumoutsakos P, Peeters A, van der Mast BJ, de Kuiper P, IJzermans JN, Weimar W, Baan CC.
    Clin Transplant; 2011 Sep 15; 25(1):40-6. PubMed ID: 20636406
    [Abstract] [Full Text] [Related]

  • 16. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G, Srinivas TR, Meier-Kriesche HU.
    Transpl Int; 2007 Oct 15; 20(10):813-27. PubMed ID: 17645419
    [Abstract] [Full Text] [Related]

  • 17. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R, Cinti P, Lai Q, Poli L, Berloco PB.
    Transpl Immunol; 2008 Nov 15; 20(1-2):3-5. PubMed ID: 18773959
    [Abstract] [Full Text] [Related]

  • 18. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M, Collini A, Ruggieri G, Garosi G, Bernini M.
    Transplant Proc; 2008 Nov 15; 40(6):1858-61. PubMed ID: 18675070
    [Abstract] [Full Text] [Related]

  • 19. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Böger CA, Banas B, Obed A, Schlitt HJ, Krämer BK.
    Transplant Proc; 2007 Mar 15; 39(2):518-21. PubMed ID: 17362772
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.